Skip to main content

Press Releases 2 hits

Evolving strategies for successfully developing biosimilars and non-platformed therapeutics

Evolving strategies for successfully developing biosimilars and non-platformed therapeutics

Press Releases   •   Feb 14, 2013 15:28 GMT

Next-generation therapies such as bi-specifics, fusion proteins and fragments offer tremendous benefits on paper, but it’s the bioprocessing departments that have to develop the new production methods, switch to new platforms and investigate new capture steps.

 Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013

Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013

Press Releases   •   Oct 03, 2012 09:00 BST

The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and exhibition, BioProcess International Europe.

News 4 hits

Increasing Capacity Utilization in Protein A Chromatography - Biopharm International

Increasing Capacity Utilization in Protein A Chromatography - Biopharm International

News   •   Jan 06, 2014 08:54 GMT

An mAb purification study tests a twin-column capture process

Elucidating Biosimilars Characterization

Elucidating Biosimilars Characterization

News   •   Dec 19, 2013 07:48 GMT

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.

BPI Europe 2013 - Latest Conference Update

BPI Europe 2013 - Latest Conference Update

News   •   Feb 11, 2013 16:12 GMT

After announcing the 2013 programm in October 2012, the latest conference is on track to being the biggest BPI event in Europe to date. Here is a brief summary of what is in store...

Sanofi’s Chief Says Investors Underestimate Drug Pipeline - Originally Published in Bloomberg

Sanofi’s Chief Says Investors Underestimate Drug Pipeline - Originally Published in Bloomberg

News   •   Jan 29, 2013 15:48 GMT

Sanofi (SAN) Chief Executive Officer Chris Viehbacher says investors are still underestimating the French company’s pipeline of experimental drugs.

Images View all 7 hits

Sarah helping out at the registration desk at BPI 2013

Sarah helping out at the ...

License © All rights reserved
Size

1.81 MB • 2784 x 1856 px

Gala dinner at BPI 2013

Gala dinner at BPI 2013

License © All rights reserved
Size

2.37 MB • 2784 x 1856 px

Inspirational speaker Marc Koske at BPI 2013

Inspirational speaker Mar...

License © All rights reserved
Size

1.44 MB • 1856 x 2784 px

One of the many presentations at BPI 2013

One of the many presentat...

License © All rights reserved
Size

1.63 MB • 1856 x 2784 px

Videos 2 hits

Interview with Life Technologies

Interview with Life Techn...

License © All rights reserved
Size

162 MB • 720 x 576 px

2012 BPI Europe Conference Review

2012 BPI Europe Conferenc...

Reasons why BPI Europe remains the leading bioprocessing event in Europe

License © All rights reserved
Size

91 MB • 720 x 576 px